BLA 125326 · Novartis
Kesimpta
Ofatumumab · Subcutaneous, Injection · CD20-directed Cytolytic Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Oct 26, 2009
Approved uses
5
Original approval plus efficacy supplements
Registered trials
138
29 Phase 3, 12 recruiting
FAERS reports
33,639
14,965 serious, 779 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2026.
KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 20, 2020 Supplement 70 · Efficacy · priority review LabelLetterReview
- Aug 30, 2016 Supplement 63 · Efficacy · priority review OrphanLetterLabel
- Jan 19, 2016 Supplement 62 · Efficacy · priority review LabelLetter
- Apr 17, 2014 Supplement 60 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Oct 26, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewSummary ReviewLabel
2 products under this application
- KESIMPTA · OFATUMUMAB 20MG/0.4ML · SOLUTION, SUBCUTANEOUS · Prescription
- ARZERRA · OFATUMUMAB 100MG/5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ofatumumab" as an intervention, any sponsor and status, largest first.
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03650114 · 1,882 participants · Start Dec 28, 2018 · Primary completion Sep 30, 2028
Drug: Ofatumumab; Tetanus toxoid (TT) containing vaccine (Td, Tdap) and 4 more · For: Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 295 sites in all
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02792231 · 955 participants · Start Aug 26, 2016 · Primary completion Jul 10, 2019
Drug: Ofatumumab subcutaneous injection; Teriflunomide-matching placebo capsules and 2 more · For: Relapsing Multiple Scelrosis
Sites: Birmingham, Alabama; Cullman, Alabama; Tucson, Arizona · 178 sites in all
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02792218 · 930 participants · Start Sep 20, 2016 · Primary completion Jul 5, 2019
Drug: Ofatumumab subcutaneous injection; Teriflunomide-matching placebo capsules and 2 more · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Fullerton, California · 166 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive TreatmentPivotal-lookingStatus unknown
University of LiverpoolAcademic, hospital or other
NCT01678430 · 670 participants (planned) · Start Dec 2011 · Primary completion Dec 2017
Drug: Ofatumumab; Chlorambucil and 1 more · For: Chronic Lymphocytic Leukaemia
Sites: Chester, United Kingdom; Plymouth, United Kingdom; Torquay, United Kingdom · 28 sites in all
- An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04353492 · 562 participants · Start Jul 14, 2020 · Primary completion Oct 9, 2024
Drug: Ofatumumab · For: Relapsing Multiple Sclerosis
Sites: Fullerton, California; Aurora, Colorado; Newark, Delaware · 123 sites in all
- Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction TherapyPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01039376 · 480 participants · Start May 6, 2010 · Primary completion Feb 20, 2017
Drug: Ofatumumab · For: Leukaemia, Lymphocytic, Chronic
Sites: Gilbert, Arizona; Tucson, Arizona; Jonesboro, Arkansas · 203 sites in all
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell LymphomaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01014208 · 447 participants · Start Mar 2010 · Primary completion Feb 2014
Drug: OFATUMUMAB + DHAP; RITUXIMAB + DHAP · For: Lymphoma, Large-Cell, Diffuse
Sites: Sacramento, California; New Haven, Connecticut; Chicago, Illinois · 173 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue5,591
- headache4,670
- pyrexia3,632
- pain3,599
- chills3,506
- influenza like illness2,934
- nausea1,832
- multiple sclerosis relapse1,741
- covid-191,523
- asthenia1,520
- multiple sclerosis1,516
- gait disturbance1,441
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 102 |
| 2011 | 151 |
| 2012 | 235 |
| 2013 | 285 |
| 2014 | 275 |
| 2015 | 328 |
| 2016 | 232 |
| 2017 | 155 |
| 2018 | 162 |
| 2019 | 109 |
| 2020 | 680 |
| 2021 | 4,664 |
| 2022 | 7,299 |
| 2023 | 8,730 |
| 2024 | 4,695 |
| 2025 | 3,618 |
| 2026 | 1,907 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Hauser SL, Zielman R, Das Gupta A, et al. · Mult Scler 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID, Willis NS, Craig JC, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Novartis · Also marketed as Arzerra
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.